Numerous studies have demonstrated that L-FABP is a promising biomarker for several kidney diseases, and it has also been shown that upregulation of renal L-FABP can protect renal function in human L-FABP transgenic mice after cisplatin treatment (Negishi et al., 2008; Manabe et al., 2012). Here, FABP1 is linked to kidney disorder.